Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug. The ad,

Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is seeking to press drugmakers to move stateside.

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.